Frameshift mutations of the nucleophosmin gene (NPM1) were recently reported as a frequently occurring abnormality in patients with de novo acute myeloid leukemia (AML). To evaluate the frequency of NPM1 mutations in patients with therapy-related myelodysplasia (t-MDS) and therapy-related AML (t-AML), and their possible association to type of previous therapy and to other gene mutations, 140 patients with t-MDS or t-AML were analyzed for mutations of NPM1. NPM1 mutations were observed in 7 of 51 patients presenting as overt t-AML, as compared to only 3 of 89 patients presenting as t-MDS (P ¼ 0.037). The mutations were not related to any specific type of previous therapy, but they were significantly associated with a normal karyotype and mutations of FLT3 (P ¼ 0.0002 for both comparisons). Only 1 of 10 patients with NPM1 mutations presented chromosome aberrations characteristic of therapyrelated disease, and 7qÀ/À7, the most frequent abnormalities of t-MDS/t-AML, were not observed (P ¼ 0.002). This raises the question whether some of the cases presenting NPM1 mutations were in fact cases of de novo leukemia. The close association to class I mutations and the inverse association to class II mutations suggest mutations of NPM1 as representing a class II mutation-like abnormality in AML. Leukemia (2008) 22, 951-955;
Introduction
Balanced translocations to chromosome band 5q35 with chimeric rearrangement of the nucleophosmin gene (NPM1) have previously been observed in rare cases of leukemia or lymphoma. The translocation partners include the anaplastic lymphoma kinase gene on chromosome band 2p23, 1 the retinoic acid receptor-a gene on chromosome band 17q12 2 and the myelodysplasia (MDS)/myeloid leukemia factor 1 gene on chromosome band 3q25.1. 3 Recently, frame shift mutations of the NPM1 gene were identified as a very frequent abnormality in adult patients with de novo acute myeloid leukemia (AML). 4 This has subsequently been confirmed by several other studies. [5] [6] [7] [8] [9] [10] In de novo AML, NPM1 mutations are predominantly observed in cases with a normal karyotype and significantly associated with mutations of the Fms-like tyrosine kinase 3 gene (FLT3). 4, [6] [7] [8] [9] [10] NPM1 mutations on their own confer a favorable prognosis of AML, whereas if combined with a FLT3-internal tandem duplication (FLT3-ITD), they predict a less favorable outcome of the disease. 4, [6] [7] [8] [9] The NPM1 gene encodes a nucleocytoplasmic shuttling protein. 11 The wild-type protein is primarily located to the nucleolus, whereas the mutated form is abundant in the cytoplasm. This redistribution is caused by a loss of the nucleolar localization signal in the C terminus of the mutated NPM1 protein, with simultaneous introduction of a novel nuclear export signal. 12 Nucleophosmin is involved in a variety of cellular activities, including ribosome biogenesis [13] [14] [15] and maintenance of genomic stability. [16] [17] [18] It has been shown to interact with components of the ARF/Mdm2/p53 pathway, [19] [20] [21] and NPM1
þ /À mice were found often to develop an MDS-like syndrome. 18 To the best of our knowledge, NPM1 has not been recorded to participate directly in the RTK/RAS-BRAF signal transduction pathway.
In AML, a cooperation between constitutively activating mutations of genes in the RTK/RAS-BRAF signal transduction pathway (class I mutations) and inactivating mutations of genes encoding hematopoietic transcription factors (class II mutations) has been proposed. 22, 23 Previous reports from our laboratory have confirmed this association in patients with therapy-related MDS or AML (t-MDS/t-AML). 24, 25 Therapy-related MDS/t-AML is of interest to study as the cytogenetic abnormalities and their associated gene mutations are often related to specific types of previous treatment. 26 So far, only few studies of NPM1 mutations in t-MDS or t-AML have been published. Falini et al. 4 did not detect cytoplasmic NPM1 in any of 135 patients with secondary AML. Thiede et al. 9 examined 55 patients with t-AML for mutations of the NPM1 gene as part of a larger study of de novo AML. Only four cases with NPM1 mutations were observed. In another study, Dö hner et al. 6 observed an apparently much higher frequency, as four of six patients with t-AML presented NPM1 mutations. Detailed clinical information and cytogenetic data for each individual patient were not provided in these reports. Thus, a more extensive study of NPM1 mutations in t-MDS and t-AML and their possible relation to type of previous therapy, to other gene mutations and to cytogenetic abnormalities is warranted. We therefore examined 140 clinically and genetically well-characterized patients with therapy-related disease for frame shift mutations in exon 12 of the NPM1 gene.
Materials and methods
Mononuclear cells isolated from the bone marrow at diagnosis of 89 patients with t-MDS and of 51 patients presenting as overt t-AML were included in the study. All patients were previously analyzed for mutations of p53, AML1 and selected genes in the RTK/RAS-BRAF pathway. 24, 27 Genomic DNA was extracted as previously described. 28 Screening for length mutations in the translated part of NPM1 exon 12 was performed by PCR followed by fragment analysis. Primers used were NPM-I11f and NPM-E12r as previously reported by Thiede et al. 9 Primer NPM-I11f was labeled with 6-FAM for fluorescence detection on the ABI 3100 (Applied Biosystems, CA, USA). Approximately 50-200 ng of genomic DNA was amplified in a total volume of 20 ml containing 1 Â Qiagen buffer (Qiagen, Hilden, Germany), 200 mM dNTPs (GE Healthcare, Munich, Germany), 0.5 mM of each primer (DNA Technology, Aarhus, Denmark) and 0.5 U of HotStarTaq polymerase (Qiagen). Amplification conditions consisted of an initial denaturation/activation step at 95 1C for 15 min followed by 30 cycles at 94 1C for 30 s, 56 1C for 30 s, 72 1C for 1 min and a final elongation step at 70 1C for 10 min. The PCR product (1 ml) was analyzed on an ABI 3100 Genetic Analyzer (Applied Biosystems) in 10 ml of HiDi formamide (Applied Biosystems) containing 5% v/v GeneScan-500 ROX Standard (Applied Biosystems).
DNA from patients showing aberrantly sized peaks in addition to the expected wild-type peak of 291 bp were re-amplified using primers NPM1-F and NPM1-R as described by Falini et al. 4 and amplification conditions consisting of an initial denaturation/activation step at 95 1C for 15 min followed by 35 cycles at 94 1C for 30 s, 55 1C for 30 s, 72 1C for 1 min and a final elongation step at 70 1C for 5 min. PCR products were purified (JETquick; Genomed, Lö hne, Germany) and sequenced directly using the NPM1-R2 primer, previously described by Dö hner et al. 6 Regions of mixed sequences were compared to publish normal sequence of NPM1 to identify the insertion sequence.
Statistical evaluations of differences between patients with and without NPM1 mutations according to various characteristics were performed using Fisher's exact test (two-tailed) or the Wilcoxon's two-sample test.
Results
Frameshift mutations of NPM1 exon 12 were detected in 10 of 140 patients with t-MDS or t-AML. Eight patients presented the variant A mutation and one the variant D mutation as previously described by Falini et al. 4, 29 The mutation variant observed in the last patient (case 113) was, to our knowledge, novel (Table 1) .
Detailed clinical and cytogenetic data for each of the 10 cases with NPM1 mutation are shown in Table 2 . The most important clinical, cytogenetic and genetic characteristics of the 10 patients with NPM1 mutations, as compared to the remaining 130 patients with germ line NPM1, are shown in Table 3 .
Seven of 10 patients with NPM1 mutations presented as overt t-AML, whereas 3 patients presented as t-MDS (P ¼ 0.037). Case 113 with t-MDS, a characteristic karyotype, and a novel NPM1 mutation type, survived for only 4 months and died from complications to cytopenia without developing overt leukemia.
Cases 132 and 163 were atypical, as they presented as refractory anemia (RA) with less than 5% blasts in the bone marrow and a normal karyotype or trisomy 8, both rarely observed in t-MDS. In these two patients, the disease progressed to overt t-AML after 20 and 16 months of observation, respectively.
Six of 10 patients with NPM1 mutations had previously received high-voltage radiotherapy and one had received radium for cervical cancer. In three cases, irradiation was the only type of therapy administered. Six patients had previously received alkylating agents, two patients had received topoisomerase II inhibitors and one patient had been treated with methotrexate and prednisone for rheumatoid arthritis (case R). Thus, a nonsignificant excess of patients was previously treated with irradiation only. No other associations between NPM1 mutations and previously administered mutagenic therapy were found.
Seven of 10 patients with mutations of NPM1 exon 12 had normal karyotypes as compared to only 17 of 130 patients with germ line NPM1 (P ¼ 0.0002, Table 3 ). In addition, one patient presented a ring chromosome 10 (case 52), another trisomy 8 (case 163), both detected as sole abnormalities. Only 1 of 10 patients presented a complex karyotype with deletion of 5q and loss of 17p, characteristic of t-MDS and t-AML. The most common abnormalities of t-MDS and t-AML, 7qÀ/À7, were not observed (P ¼ 0.002, Table 3 ).
Mutations of NPM1 exon 12 were associated with ITD mutations of FLT3 in 5 of 10 patients (P ¼ 0.0002, Table 3 ). In addition, a mutation of NRAS was detected in case 132. Thus, associated class I mutations were detected in 6 of 10 patients with NPM1 mutations as compared to only 27 of 130 patients with germ line NPM1 (P ¼ 0.012, Table 3 ). Neither point mutations of p53 or of AML1, the most common mutations of therapy-related diseases, nor chimeric rearrangements of genes encoding hematopoietic transcription factors (class II mutations) were detected in patients with NPM1 mutations. In contrast, associated class II mutations were detected in 47 of 130 patients with germ line NPM1 (P ¼ 0.017, Table 3 ). The analyses for mutations of FLT3, NRAS, p53 and AML1 were performed previously on all 140 patients.
Discussion
In the present study, frameshift mutations of the NPM1 gene were observed in 7 of 51 patients presenting as overt t-AML (14%). This frequency is much lower than that observed in patients with de novo AML, ranging from 25 to 35%. 4, 7, 9, 10 If correcting for karyotype and type of disease, however, we observed NPM1 mutations in 6 of 15 (40%) patients with overt t-AML and a normal karyotype, as compared to 47-64% in similar cases of de novo AML reported in the literature. [5] [6] [7] [8] 10 Thus, the difference in frequency of NPM1 mutations between therapy-related and de novo AML seems to rely mainly on a difference in cytogenetic characteristics, with a normal Table 1 Nucleotide and theoretical peptide sequences of the NPM1 exon 12 translated region 4 The occurrence of NPM1 mutations in de novo MDS is uncommon and controversial. 30, 31 Our observation of three cases of NPM1 mutations in patients with t-MDS is therefore surprising. All three cases, however, were atypical. Case 113 presented a complex karyotype with del(5q) and loss of 17p in 23 of 24 mitoses, abnormalities rarely observed in combination with NPM1 mutations. Cases 132 and 163 were also rather unique, as they belonged to the small subgroup of patients with t-MDS and a normal karyotype or trisomy 8.
As far as etiology is concerned, no significant associations to specific types of previous therapy were observed in our patients with t-MDS or t-AML and NPM1 mutations, despite intensive mutagenic exposures of the whole group. Noteworthy are three patients with NPM1 mutations, who had received irradiation only. In our previous studies, only mutations of FLT3 have been significantly associated with previous radiotherapy. 24 In other studies, relative risks in the order of 2.0-2.4 have been observed following radiotherapy. 32, 33 This indicates that approximately 50% of such AMLs are directly radiation induced, whereas another 50% are cases of de novo AML. Hence, cases 29, 52 and 148, as well as case R treated with methotrexate þ prednisone without a confirmed leukemogenic potential, could all be suspected to represent de novo leukemias. Also, cases 82 and 78, who developed t-AML with normal karyotypes after unusually short or long latent periods of 18 or 104 months, respectively, could be cases of de novo leukemia.
Five of 10 patients with NPM1 mutations also presented FLT3 mutations as compared to only 6 of 130 patients with germ line NPM1 (P ¼ 0.0002, Table 3 ). Of importance, another patient with an NPM1 mutation presented an NRAS mutation. These observations, with 6 of 10 patients with NPM1 mutations presenting an associated class I mutation (P ¼ 0.012), but not a single class II mutation (P ¼ 0.017), raise the question whether NPM1 mutations should be considered as a class II mutation equivalent, cooperating with class I mutations in leukemogenesis. Other findings are compatible with this assumption. NPM1 has been shown to stabilize p53 in a transcriptionally competent state, 21 and haploinsufficiency of the gene may function as primary lesion in the development of an MDS-like disease in mice. 18 Finally, the NPM1 gene has not been shown to be directly participating in the RTK/RAS-BRAF pathway.
If the NPM1 mutations are included together with the classic class II mutations previously observed in our cohort of 140 patients with t-MDS or t-AML, 25 the total number of class I mutations still amounts to 35, whereas class II mutations now amount to 59. In 25 of these cases, a concomitant classes I and II mutation was observed (P ¼ 0.0001). 34 Further knowledge about the mechanisms of action of nucleophosmin will hopefully clarify whether mutations of the NPM1 gene represent a class II type of mutation. Latent period: Time from primary tumor/disease to t-MDS/t-AML. Where two latent periods are listed; the first is time from primary tumor/disease to t-MDS, whereas the second is time from t-MDS to t-AML.
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